Slides
Page 1
Investor Presentation | Q2FY26 November 12th, 2025
Page 2
1 Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will" , "aim" , "will likely result" , "would" , "believe" , "may" , "expect" , "will continue" , "anticipate" , "estimate" , "intend" , "plan" , "contemplate" , “seek to" , "future" , "objective" , "goal" , "likely" , "project" , "should" , "potential" , "will pursue" , and similar expressions of such expressions may constitute "forward-looking statements“ . These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially f rom those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
Page 3
Financial Performance
Page 4
3 Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to $500m+ ( Q2FY26 Performance Snapshot ) ₹3,758m $43.1m ₹1,065m $12.2m 28% ₹449m $5.2m Neeraj Sharma CEO & MD Q2FY26 performance in line with year-on-year revenue growth and margin expansion 12% YoY 37% YoY Revenue EBITDA 506 bps YoY EBITDA margin Loss to profit Adjusted PAT1 Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹87.16 1. Adjusted PAT excludes scheme related intangible amortisation (₹344m)